RxDoctor Payments Data

Claudia Sevilla, MD

Urology · Chula Vista, CANPI 1689081275

Payments from drug & device makers

$8,801in general payments, 2019–2025

Across 196 payments — averaging $44.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Axonics, Inc.$1K
  • Teleflex LLC$987
  • AbbVie$591
  • Intuitive Surgical$548
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$1,03112%
  • Food & beverage$7,51085%
  • Education$2493%
  • Gifts$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,801 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$43,268
Medicare patients
138
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron747$519,682
MyrbetriqMirabegron271$142,705
Estradiol510$36,226
EstringEstradiol18$9,852
Methenamine Hippurate104$7,717
YuvafemEstradiol27$3,276
Mirabegron ErMirabegron11$2,557
NitrofurantoinNitrofurantoin Macrocrystal77$2,305
Fosfomycin Tromethamine26$1,932
Desmopressin Acetate16$1,518
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst57$992
Finasteride56$668
Tamsulosin Hcl65$538
Cephalexin50$247
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$388$519,682747 claims
Astellas Pharma US IncMyrbetriq$353$142,705271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,324 urology providers in California.

Other urology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →